NCT07516821Not yet recruiting
Efficacy of Topical Metformin in Psoriasis Vulgaris
Efficacy and Safety of Topical Metformin in Psoriasis Vulgaris: A Randomized, Double Blinded, Placebo-controlled Study.
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if topical metformin works to treat mild psoriasis vulgaris. It will also learn about the safety of topical metformin. The main questions it aims to answer are: Does topical metformin improve psoriatic plaques in early psoriasis? What medical problems do participants have when use topical metformin? Researchers will compare topical metformin to a placebo (a look-alike substance that contains no drug) to see if topical metformin works to treat psoriasis vulgaris. Participants will: put topical metformin or placebo twice daily for 2 months. Visit the clinic once every months for follow up. Keep a diary of their symptoms and any side effects. Skin biopsy will be taken from psoriatic plaque before starting treatment and another one will be taken after 2 months of starting treatment to assess the level of IL-17.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- First submitted
- 1 Apr 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Cairo University
- Diseases
- Psoriasis
- NCT number
- NCT07516821
What you commit to
- Study type: Interventional
- Planned participants: 55
- From 1 Apr 2026 to the primary completion date, 1 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intake of anti-psoriatic systemic therapy within the last 3 months apart from retinoids, or topical treatments within the last 2 weeks.
- Intake of other systemic drugs that exacerbate psoriasis as anti-malarial drugs, Angiotensin- converting-enzyme inhibitors (ACEI), Ca channel blockers (CCBs) and beta blockers or intake of non-steroidal anti- inflammatory drugs (NSAID) within the last 2 weeks.
Other
- Intake of systemic metformin.
- Patients with psoriatic arthritis.
- Patients with pustular psoriasis.
- Pregnant and Lactating females.
Who the study is looking for
- Patients ≥ 18 years old
- Patients of both genders
- Patients with mild chronic plaque psoriasis ((PASI) \< 10, and body surface area (BSA) \< 10% and/or Dermatology Life Quality Index (DLQI) \<10).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cairo University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.